Roche are developing RG7356, which targets CD44, a surface receptor that is over-expressed in ZAP-70 positive CLL patients as well as some solid tumours. If early phase clinical trials proceed and show promise, this could be good news for ZAP-70 positive patients, given the generally poorer prognosis associated with this marker.
The full paper is available from the on-line edition of the Proceedings of the National Academy of Sciences:
pnas.org/content/110/15/612...
Neil
FCR VS BR
CD38 POSITIVE AND ZAP -70 POSITIVE 
Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemia
Access to Monoclonal Antibody Treatment in Mexico
